贝那普利片联合美托洛尔片治疗高血压合并心力衰竭

Benazepril Tablets Combined With Metoprolol Tablets in the Treatment of Hypertension With Heart Failure

目的探究贝那普利片联合美托洛尔片治疗高血压合并心力衰竭的临床效果。方法选择本院2019年6月—2020年7月收治的高血压合并心力衰竭患者103例,采用随机数字表法分为对照组51例与观察组52例,对照组采用贝那普利片治疗,观察组在对照组治疗基础上联合美托洛尔片治疗。比较两组临床治疗效果,治疗前后血压(收缩压、舒张压)、心功能[左心室收缩末期内径(LVESD)、左室射血分数(LVEF)、6 min步行距离(6MWT))]、生化指标[N末端脑利钠肽前体(NT-proBNP)、脂联素(APN)、可溶性肿瘤形成抑制素2(ST-2)]及不良反应发生情况。结果观察组临床治疗有效率96.15%,高于对照组的80.39%(P<0.05);治疗后观察组收缩压(122.17±10.34)mmHg低于对照组的(138.76±15.51)mmHg(P<0.05),舒张压(78.92±5.37)mmHg低于对照组的(88.64±6.34)mmHg(P<0.05);治疗后观察组LVESD(37.94±5.11)mm低于对照组的(46.23±6.72)mm(P<0.05),LVEF(49.78±4.25)%高于对照组的(41.34±4.02)%(P<0.05),6MWT(525.53±62.82)m高于对照组的(420.63±60.63)m(P<0.05);治疗后观察组NT-proBNP(492.94±50.33)ng/L低于对照组的(641.85±68.42)ng/L(P<0.05),APN(6.37±1.25)μg/mL低于对照组的(8.26±2.06)μg/mL(P<0.05),ST-2(28.53±4.89)ng/mL低于对照组的(38.93±6.63)ng/mL(P<0.05);观察组不良反应发生率11.54%与对照组的9.80%比较,差异无统计学意义(P>0.05)。结论贝那普利片联合美托洛尔片治疗高血压合并心力衰竭效果肯定,能有效降低患者血压,提升心功能,改善生化指标,安全性高,值得临床应用与推广。

Objective To explore the clinical effect of benazepril combined with metoprolol tablets in the treatment of hypertension with heart failure.Methods Selected 103 patients with hypertension and heart failure admitted to our hospital from June 2019 to July 2020,they were divided by random number table method,and 51 patients in the control group and 52 patients in the observation group.The control group was treated with benazepril tablets,and the observation group was treated with metoprolol tablets on the basis of the control group.The clinical treatment effects of the two groups were compared,blood pressure(systolic blood pressure,diastolic blood pressure),cardiac function[left ventricular end systolic diameter(LVESD),left ventricular ejection fraction(LVEF),6-min walking distance(6MWT)],biochemical indicators[N-terminal pro-brain natriuretic peptide(NT-proBNP),adiponectin(APN),soluble tumorigenesis inhibitor 2(ST-2)]and the occurrence of adverse reactions.Results The clinical treatment effective rate of 96.15%of the observation group was higher than 80.39%of the control group(P<0.05);after treatment,the observation group's systolic blood pressure(122.17±10.34)mmHg was lower than(138.76±15.51)mmHg of the control group(P<0.05),diastolic blood pressure(78.92±5.37)mmHg was lower than(88.64±6.34)mmHg of the control group(P<0.05);after treatment,the observation group of LVESD(37.94±5.11)mm was lower than(46.23±6.72)mm of control group(P<0.05),LVEF(49.78±4.25)%was higher than(41.34±4.02)%of control group(P<0.05),6MWT(525.53±62.82)m was higher than(420.63±60.63)m of control group(P<0.05);NT�proBNP(492.94±50.33)ng/L in the observation group after treatment was lower than(641.85±68.42)ng/L of control group(P<0.05),APN(6.37±1.25)μg/mL was lower than(8.26±2.06)μg/mL of control group(P<0.05),ST-2(28.53±4.89)ng/mL was lower than(38.93±6.63)ng/mL of control group(P<0.05);the incidence of reaction in the observation group was 11.54%,compared with the 9.80%of control group,the difference was not statistically significant(P>0.05).Conclusion Benazepril tablets combine with metoprolol tablets have a positive effect in the treatment of hypertension complicated with heart failure.They can effectively reducing blood pressure,improving heart function,improving biochemical indicators,and have high safety.It is worthy of clinical application and promotion.